ESR1 and breast cancer: Three out of four cases of breast cancer (BC) express the estrogen receptor alpha (ER) and are treated with endocrine therapies, such as selective ER modulators (e.g., tamoxifen), aromatase inhibitors (e.g., letrozole), and selective ER down-regulators (e.g., fulvestrant) [1].